FDA OKs 1st generic version of popular Advair asthma inhaler
The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators.
The Food and Drug Administration on Wednesday approved Mylan’s version in three strengths for ages 4 and up.
The inhalers are used twice daily to keep airways open and prevent flare-ups of wheezing, shortness of breath and other symptoms of asthma or chronic obstructive pulmonary disease. About 42 million Americans have those conditions.
The device contains two medicines, inhaled in a precise mixture. That complexity has stymied a couple of other companies developing generic versions of GlaxoSmithKline’s Advair Diskus inhaler, which costs about $400 a month.
Generics generally are cheaper. Mylan didn’t immediately respond to queries about when its inhaler, called Wixela Inhub, will be available or what the price will be.
The Western Journal has not reviewed this Associated Press story prior to publication. Therefore, it may contain editorial bias or may in some other way not meet our normal editorial standards. It is provided to our readers as a service from The Western Journal.
Truth and Accuracy
We are committed to truth and accuracy in all of our journalism. Read our editorial standards.
Advertise with The Western Journal and reach millions of highly engaged readers, while supporting our work. Advertise Today.
